Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stockwatch: Which way is up?

This article was originally published in Scrip

Executive Summary

As the third quarter earnings season starts to trail off, investors could be forgiven for wondering what it takes anymore for the share prices of companies to go up, rather than down. Over the past two weeks, the delineation between big pharmaceutical companies and big biotechnology companies couldn't have been clearer with big biotechs like Amgen, Gilead, Celgene and Biogen reporting better than expected quarterly profits and raising guidance, whereas big pharmas like Pfizer, Lilly, GlaxoSmithKline and Bristol Myers Squibb all drifted in the shadow of their respective patent expiries (, 25 October 2012).



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts